Skin Disorders News

ANAHEIM, Calif. — “There are a lot of interesting trends,” John J. Oppenheimer, MD, FACAAI, clinical professor at UMDNJ Rutgers, told Healio at the American College of Allergy, Asthma & Immunology 2023 Annual Scientific Meeting.

Patients with atopic dermatitis with comorbidities face additional treatment burdens and barriers, according to a study published in Annals of Allergy, Asthma & Immunology.

Patients with chronic spontaneous urticaria showed rapid symptom improvement with a favorable safety profile over 52 weeks of treatment with remibrutinib, according to a study published in The Journal of Allergy and Clinical Immunology.

New data showed delgocitinib cream maintained symptom relief and treatment success in adults with chronic hand eczema, LEO Pharma announced in a press release.

Patients being treated for atopic dermatitis with dupilumab had good reproducibility with patch testing for allergic contact dermatitis, according to a study.

Tape strips that capture the molecular fingerprint of chronic hand eczema indicated broadly shared immune and barrier dysregulations among patients who have and who do not have atopic dermatitis, according to a study abstract.

Some patients who use omalizumab to treat their chronic urticaria may discontinue its use to reveal disease remission and avoid drug exposure, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Rinvoq showed long-term efficacy and safety up to 140 weeks in the treatment of moderate to severe atopic dermatitis in adults and adolescents aged 12 years and older, AbbVie announced in a press release.

With dozens of topical therapies and systemic treatments available for atopic dermatitis, clinicians have many options. But a pair of reviews in The Journal of Allergy and Clinical Immunology may help them narrow down their choices.

Children with vs. without atopic dermatitis are more likely to have positive patch-test reactions for allergic contact dermatitis, according to a study.